Cargando…

Salivary inflammatory biomarkers and glycated haemoglobin among patients with type 2 diabetic mellitus

BACKGROUND: Type 2 diabetes mellitus has reached epidemic proportions worldwide and improved detection techniques and biomarkers are urgently needed across the spectrum of diabetes initiation and progression. Inflammatory biomarkers play a role in the development of the condition and blood is the go...

Descripción completa

Detalles Bibliográficos
Autores principales: Agho, Ekhosuehi Theophilus, Owotade, Foluso John, Kolawole, Babatope Ayodeji, Oyetola, Elijah Olufemi, Adedeji, Tewogbade Adeoye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095344/
https://www.ncbi.nlm.nih.gov/pubmed/33676486
http://dx.doi.org/10.1186/s12903-021-01453-y
_version_ 1783688060617097216
author Agho, Ekhosuehi Theophilus
Owotade, Foluso John
Kolawole, Babatope Ayodeji
Oyetola, Elijah Olufemi
Adedeji, Tewogbade Adeoye
author_facet Agho, Ekhosuehi Theophilus
Owotade, Foluso John
Kolawole, Babatope Ayodeji
Oyetola, Elijah Olufemi
Adedeji, Tewogbade Adeoye
author_sort Agho, Ekhosuehi Theophilus
collection PubMed
description BACKGROUND: Type 2 diabetes mellitus has reached epidemic proportions worldwide and improved detection techniques and biomarkers are urgently needed across the spectrum of diabetes initiation and progression. Inflammatory biomarkers play a role in the development of the condition and blood is the gold standard body fluid for the diagnosis of diabetes mellitus. Serum glycated haemoglobin is a widely used marker of chronic hyperglycemia, and it is currently used to diagnose type 2 diabetes mellitus and it is the standard biomarker for the adequacy of management. However, saliva offers an alternative to serum as a biological fluid for diagnostic purposes. Non-invasive measures of inflammatory biomarkers (such as saliva diagnostics) are increasingly being investigated due to significant similarities between salivary and serum proteome. The role of saliva diagnostics in diabetes mellitus has not been explored in our study population. OBJECTIVES: This study investigated the association of selected salivary inflammatory biomarkers (Interleukin 6 [IL-6], C-reactive protein [CRP], and Tumour necrosis factor α [TNF-α]) to glycated haemoglobin (HbA1C) in type 2 diabetics. MATERIALS AND METHODS: Seventy-five participants, 39 type 2 diabetics (52%) and 36 (48%) healthy controls were recruited. Saliva and blood samples were collected for each participant. The levels of selected salivary inflammatory biomarkers (IL-6, CRP and TNF-α) were estimated by Enzyme Linked Immunosorbent Assay (ELISA) method and glycated haemogloin (HbA1C) was estimated using the liquid chromatography method. Periodontal status of the participants were determined using the Basic Periodontal Examination (BPE). RESULTS: The mean salivary levels of CRP was significantly higher in diabetics, 0.05 ± 0.04 µg/ml than in controls, 0.02 ± 0.02 µg/ml (p < 0.001). Mean TNF-α was also significantly higher in diabetics, 5.39 ± 12.10 pg/ml than in controls, 1.51 ± 3.66 pg/ml (p = 0.036). Mean salivary IL-6 was also higher in diabetics compared with controls (47.20 ± 18.49 versus 41.94 ± 16.88 pg/ml), but the difference was not statistically significant, p = 0.204. In the multivariate analysis adjusting for age and periodontal status, only the mean salivary CRP was significantly higher in diabetics, 0.034 higher than controls (95% CI 0.009, 0.059 and p = 0.01). There was a positive correlation between salivary CRP and HbA1C levels, which was moderate with r-value 0.4929 and p-value < 0.0001. CONCLUSIONS: Salivary inflammatory biomarkers especially CRP are higher in diabetics compared with controls and CRP is positively correlated with serum HbA1C levels. The biomarkers show potentials as non-invasive alternative method to evaluate glycaemic control in diabetes.
format Online
Article
Text
id pubmed-8095344
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80953442021-05-05 Salivary inflammatory biomarkers and glycated haemoglobin among patients with type 2 diabetic mellitus Agho, Ekhosuehi Theophilus Owotade, Foluso John Kolawole, Babatope Ayodeji Oyetola, Elijah Olufemi Adedeji, Tewogbade Adeoye BMC Oral Health Research Article BACKGROUND: Type 2 diabetes mellitus has reached epidemic proportions worldwide and improved detection techniques and biomarkers are urgently needed across the spectrum of diabetes initiation and progression. Inflammatory biomarkers play a role in the development of the condition and blood is the gold standard body fluid for the diagnosis of diabetes mellitus. Serum glycated haemoglobin is a widely used marker of chronic hyperglycemia, and it is currently used to diagnose type 2 diabetes mellitus and it is the standard biomarker for the adequacy of management. However, saliva offers an alternative to serum as a biological fluid for diagnostic purposes. Non-invasive measures of inflammatory biomarkers (such as saliva diagnostics) are increasingly being investigated due to significant similarities between salivary and serum proteome. The role of saliva diagnostics in diabetes mellitus has not been explored in our study population. OBJECTIVES: This study investigated the association of selected salivary inflammatory biomarkers (Interleukin 6 [IL-6], C-reactive protein [CRP], and Tumour necrosis factor α [TNF-α]) to glycated haemoglobin (HbA1C) in type 2 diabetics. MATERIALS AND METHODS: Seventy-five participants, 39 type 2 diabetics (52%) and 36 (48%) healthy controls were recruited. Saliva and blood samples were collected for each participant. The levels of selected salivary inflammatory biomarkers (IL-6, CRP and TNF-α) were estimated by Enzyme Linked Immunosorbent Assay (ELISA) method and glycated haemogloin (HbA1C) was estimated using the liquid chromatography method. Periodontal status of the participants were determined using the Basic Periodontal Examination (BPE). RESULTS: The mean salivary levels of CRP was significantly higher in diabetics, 0.05 ± 0.04 µg/ml than in controls, 0.02 ± 0.02 µg/ml (p < 0.001). Mean TNF-α was also significantly higher in diabetics, 5.39 ± 12.10 pg/ml than in controls, 1.51 ± 3.66 pg/ml (p = 0.036). Mean salivary IL-6 was also higher in diabetics compared with controls (47.20 ± 18.49 versus 41.94 ± 16.88 pg/ml), but the difference was not statistically significant, p = 0.204. In the multivariate analysis adjusting for age and periodontal status, only the mean salivary CRP was significantly higher in diabetics, 0.034 higher than controls (95% CI 0.009, 0.059 and p = 0.01). There was a positive correlation between salivary CRP and HbA1C levels, which was moderate with r-value 0.4929 and p-value < 0.0001. CONCLUSIONS: Salivary inflammatory biomarkers especially CRP are higher in diabetics compared with controls and CRP is positively correlated with serum HbA1C levels. The biomarkers show potentials as non-invasive alternative method to evaluate glycaemic control in diabetes. BioMed Central 2021-03-06 /pmc/articles/PMC8095344/ /pubmed/33676486 http://dx.doi.org/10.1186/s12903-021-01453-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Agho, Ekhosuehi Theophilus
Owotade, Foluso John
Kolawole, Babatope Ayodeji
Oyetola, Elijah Olufemi
Adedeji, Tewogbade Adeoye
Salivary inflammatory biomarkers and glycated haemoglobin among patients with type 2 diabetic mellitus
title Salivary inflammatory biomarkers and glycated haemoglobin among patients with type 2 diabetic mellitus
title_full Salivary inflammatory biomarkers and glycated haemoglobin among patients with type 2 diabetic mellitus
title_fullStr Salivary inflammatory biomarkers and glycated haemoglobin among patients with type 2 diabetic mellitus
title_full_unstemmed Salivary inflammatory biomarkers and glycated haemoglobin among patients with type 2 diabetic mellitus
title_short Salivary inflammatory biomarkers and glycated haemoglobin among patients with type 2 diabetic mellitus
title_sort salivary inflammatory biomarkers and glycated haemoglobin among patients with type 2 diabetic mellitus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095344/
https://www.ncbi.nlm.nih.gov/pubmed/33676486
http://dx.doi.org/10.1186/s12903-021-01453-y
work_keys_str_mv AT aghoekhosuehitheophilus salivaryinflammatorybiomarkersandglycatedhaemoglobinamongpatientswithtype2diabeticmellitus
AT owotadefolusojohn salivaryinflammatorybiomarkersandglycatedhaemoglobinamongpatientswithtype2diabeticmellitus
AT kolawolebabatopeayodeji salivaryinflammatorybiomarkersandglycatedhaemoglobinamongpatientswithtype2diabeticmellitus
AT oyetolaelijaholufemi salivaryinflammatorybiomarkersandglycatedhaemoglobinamongpatientswithtype2diabeticmellitus
AT adedejitewogbadeadeoye salivaryinflammatorybiomarkersandglycatedhaemoglobinamongpatientswithtype2diabeticmellitus